{"entity":{"id":"nct07562711","kind":"trial","name":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","aka":["CLEAR-02"],"tldr":"A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.","summary":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07562711 by Fudan University, with a registry enrolment figure of 340 participants, started 2024-11-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Capecitabine; FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin). Conditions listed: ctDNA; Chemotherapy; Colorectal Cancer. Primary outcome: Patient's 2-year Progression-Free Survival. Colorectal eligibility wording from the registry: \"Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07562711","url":"https://clinicaltrials.gov/study/NCT07562711"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","mrd-testing","platinum"],"targets":[],"drugs":["capecitabine","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07562711","phase":"2","setting":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","sponsor":"Fudan University","enrolled":340,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07562711/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}